KR20250095953A - A composition for preventing, improving or treating muscle diseases comprising extracts of oat hull - Google Patents

Abstract

The present invention relates to a composition for preventing, improving or treating muscle diseases, which contains an oat hull extract as an effective ingredient. Specifically, it was confirmed that the oat hull extract according to the present invention increases the weight of the thigh muscle and improves muscle strength, thereby confirming that it can be used as a food composition, a pharmaceutical composition and a feed composition.

Description

{A composition for preventing, improving or treating muscle diseases comprising extracts of oat hull}

The present invention relates to a composition for preventing, improving or treating muscle diseases comprising an oat hull extract. Specifically, it was confirmed that the oat hull extract according to the present invention increases the weight and improves the muscle strength of the thigh muscle, thereby confirming that it can be used as a food composition, a pharmaceutical composition and a feed composition.

Skeletal muscle is the largest organ in the human body, accounting for 40-50% of the human body. Skeletal muscle tends to decrease by about 1% per year after the age of 30, and then rapidly decreases after the age of 65. As aging progresses, the functional ability of muscles also gradually decreases. This decrease in muscle mass due to aging, as well as muscle strength or muscle function, is called sarcopenia.

In many epidemiological studies, sarcopenia has been noted as a cause of metabolic dysfunction and chronic diseases of the elderly, such as diabetes, obesity, cardiovascular disease, and osteoporosis. Metabolic dysfunction or motor dysfunction due to fractures caused by sarcopenia further worsens sarcopenia, forming a vicious cycle and rapidly increasing the mortality rate.

Treatment for sarcopenia is divided into lifestyle improvement and drug therapy, but exercise therapy is limited for elderly people with severe sarcopenia or patients with neurocognitive disorders or heart disease. Drug therapy includes drugs that suppress myostatin, which causes sarcopenia, and hormone therapy such as testosterone and growth hormone, but there is a lack of clear clinical evidence on safety. Therefore, the development of a treatment for sarcopenia can be said to be a blue ocean area where there are currently no drugs approved by the FDA.

Meanwhile, oats are a biennial plant of the gramineae family, and their scientific name is Avena sativa . They are also called oats. They grow in clumps at the bottom and can reach a height of 1 m. The stems are straight and almost hairless, but there are downward-facing hairs at the nodes. The leaves are 15-30 cm long and 6-12 mm wide, slightly wider than wheat and dark green. The leaf sheaths are long and the leaf tongues are short and finely divided. The flowers bloom in May and June and are 20-30 cm long in panicles. The small spikes are green and have two small flowers and droop down. Oats, like other grains, are mainly composed of carbohydrates, but their protein content is 13-14%, which is higher than rice, barley, and wheat, and their lipid content is also high at 5-6%. However, the amino acid composition of oats is low in lysine, tryptophan, threonine, and methionine, similar to rice. Oats are mainly used as feed or fodder for livestock, but they are also peeled, pressed flat, and eaten as oatmeal or cookies. Oats are rich in fiber, which helps lower blood cholesterol and prevent constipation, and they are rich in unsaturated fatty acids, which help lower blood pressure. In addition, beta-glucan, one of the components of oats, is a water-soluble dietary fiber that improves the immune system and has anticancer effects, and prostaglandin has the effect of suppressing inflammatory responses (Skendi, A., et al. "Structure and rheological properties of water-soluble β-glucans from oat cultivars of Avena sativa and Avena bysantina." Journal of Cereal Science 38.1 (2003): 15-31.). However, little research has been done on oat hulls.

Against this backdrop, the inventors of the present invention have conducted extensive research efforts to find a substance effective in preventing, improving or treating muscle diseases from a natural product that is safe for the human body, and as a result, have confirmed that oat hull extract has the effect of increasing the weight of the thigh muscle and improving muscle strength, thereby completing the present invention.

One object of the present invention is to provide a food composition for preventing or improving muscle disease containing an oat hull extract as an effective ingredient.

Another object of the present invention is to provide a pharmaceutical composition for preventing or treating muscle disease containing an oat hull extract as an active ingredient.

Another object of the present invention is to provide a method for preventing or treating muscle disease, comprising a step of administering an oat hull extract to a subject other than a human.

Another object of the present invention is to provide a feed composition for preventing or improving muscle disease containing an oat hull extract.

This is explained specifically as follows. Meanwhile, each description and embodiment disclosed in the present invention can also be applied to each other description and embodiment. That is, all combinations of various elements disclosed in the present invention fall within the scope of the present invention. In addition, the scope of the present invention cannot be considered limited by the specific description described below.

One aspect of the present invention to achieve the above object provides a food composition for preventing or improving muscle disease, comprising an oat hull extract as an effective ingredient.

The term "oat" of the present invention refers to a biennial plant of the gramineae family, and its scientific name is Avena sativa . The "oat hull" of the present invention may refer to a by-product excluding the grain produced after processing oats, but may also include oat hulls to which the grain is partially attached due to technical limitations. Oats and oat hulls may be raw, dried, or processed, and those sold commercially may be purchased and used, or those collected or grown in nature may be used for the production of extracts, but are not limited thereto.

In the present invention, the oat hulls may be purchased and used commercially, or may be collected or grown in nature, but are not limited thereto.

The term "extract" of the present invention means a result such as a liquid component obtained by immersing a target substance in various solvents and then extracting it at room temperature or in a heated state for a certain period of time, a solid component obtained by removing the solvent from the liquid component, etc. In addition, it can be comprehensively interpreted to include, in addition to the result, a dilution of the result, a concentrate thereof, a conditioning agent, a purified product thereof, etc. Accordingly, the oat hull extract provided in the present invention can be interpreted to include an extract obtained by extraction treatment thereof, a dilution or concentrate of the extract, a dried product obtained by drying the extract, a conditioning agent or purified product of the extract, or a mixture thereof, the extract itself and all extracts in formulations that can be formed using the extract.

The extraction method of the oat hull extract of the present invention is not particularly limited, and extraction can be performed according to a method commonly used in the relevant technical field. Non-limiting examples of the extraction method include hot water extraction, ultrasonic extraction, filtration, and reflux extraction, and these can be performed alone or in combination of two or more methods.

In the present invention, the type of solvent used for the extraction is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the extraction solvent include water, alcohol, or a mixed solvent thereof, and these can be used alone or in combination of one or more, and water can be used specifically. When alcohol is used as a solvent, an alcohol having 1 to 4 carbon atoms can be used specifically.

In addition, the above extract may be manufactured and used in the form of a dry powder after extraction, but this is not limited thereto.

In one embodiment of the present invention, water or alcohol was added to oat hulls to obtain an oat hull extract.

The term "muscle disease" of the present invention refers to a disease caused by a decrease in muscle or muscle strength, and specifically, may be at least one selected from the group consisting of sarcopenia, muscular atrophy, myasthenia, muscular dystrophy, myotonia, hypotonia, muscular weakness, muscular dystrophy, amyotrophic lateral sclerosis, muscle weakness, and inflammatory myopathy, and more specifically, may be sarcopenia or muscle weakness.

The term "sarcopenia" of the present invention refers to a decrease in muscle mass, muscle strength, or muscle function, which may be due to aging or obesity, and is caused by diseases occurring in the muscles themselves, diseases such as diabetes, infections, cancer, and degenerative diseases such as spinal stenosis.

The term "prevention" of the present invention means any act of inhibiting or delaying the onset of sarcopenia by administering a food composition according to the present invention.

The term "improvement" of the present invention means any action that at least reduces a parameter related to a sarcopenic state, for example, the degree of symptoms, by ingestion of the composition of the present invention.

When the composition of the present invention is used as a health functional food additive, the oat hull extract or its physiologically acceptable salt can be added as is or used together with other foods or food ingredients, and can be used appropriately according to a conventional method. The mixing amount of the effective ingredients can be appropriately determined depending on the purpose of use (prevention, health, or therapeutic treatment), and since the composition of the present invention has no problem in terms of stability, there is no significant limitation on the mixing amount.

Since the food composition of the present invention can be taken on a daily basis, it can be expected to have an effect on preventing, treating, or improving sarcopenia, and therefore can be very usefully used for health promotion purposes.

The term "food" of the present invention includes meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, vitamin complexes, health functional foods, and health foods, and includes all foods in the conventional sense.

The above term, "health functional food" is the same as food for special health use (FoSHU), and means a food with high medical and healthcare effects that is processed to efficiently exhibit a bioregulatory function in addition to nutritional supply. Here, "function" means regulating nutrients for the structure and function of the human body or obtaining a useful effect for health purposes such as physiological action. The health functional food of the present invention can be manufactured by a method commonly used in the art, and can be manufactured by adding raw materials and ingredients commonly added in the art during the manufacturing process. In addition, the formulation of the health functional food can be manufactured without limitation as long as it is a formulation recognized as a food. The food composition of the present invention can be manufactured in various forms of formulations, and unlike general drugs, it has the advantage of not having side effects that may occur when taking drugs for a long time by using food as a raw material, and is highly portable, so the health functional food of the present invention can be taken as a supplement to enhance the effect of improving sarcopenia.

The above health functional food refers to a food that has a more active health maintenance or promotion effect than general food, and health supplement food refers to a food for the purpose of health supplementation. In some cases, the terms health functional food, health food, and health supplement food are used interchangeably.

Specifically, the health functional food means a food product manufactured by adding the composition of the present invention to food materials such as beverages, teas, spices, gum, and confectionery, or by manufacturing the same in the form of encapsulation, powder, suspension, etc., and which has a specific health effect when consumed; however, unlike general drugs, it has the advantage of not having side effects that may occur with long-term use of drugs since it uses food as a raw material.

The above food composition may additionally contain a physiologically acceptable carrier. The type of the carrier is not particularly limited, and any carrier commonly used in the art may be used.

In addition, the food composition may include additional ingredients commonly used in food compositions to improve odor, taste, sight, etc. For example, it may include vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, pantothenic acid, etc. In addition, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), and amino acids such as lysine, tryptophan, cysteine, and valine.

In addition, the food composition may contain food additives acceptable in terms of food science, such as preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), bactericides (bleaching powder and highly bleaching powder, sodium hypochlorite, etc.), antioxidants (butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), etc.), colorants (tar color, etc.), colorants (sodium nitrite, sodium nitrite, etc.), bleaching agents (sodium sulfite), seasonings (MSG, monosodium glutamate, etc.), sweeteners (dulcin, cyclamate, saccharin, sodium, etc.), flavorings (vanillin, lactones, etc.), leavening agents (alum, D-potassium hydrogen tartrate, etc.), reinforcing agents, emulsifiers, thickeners (glutinating agents), film agents, gum bases, foam suppressants, solvents, and improvers. The above additives can be selected depending on the type of food and used in an appropriate amount.

As an example, the food composition of the present invention can be used as a health beverage composition, and in this case, various flavoring agents or natural carbohydrates, etc. can be contained as additional ingredients like a conventional beverage. The above-mentioned natural carbohydrates can be monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrin and cyclodextrin; sugar alcohols such as xylitol, sorbitol and erythritol. The sweetener can be a natural sweetener such as thaumatin and stevia extract; a synthetic sweetener such as saccharin and aspartame, etc. The proportion of the natural carbohydrate can be generally about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g per 100 ml of the health beverage composition of the present invention.

In addition to the above, the health drink composition may contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol, or carbonating agents. In addition, it may contain fruit pulp for producing natural fruit juice, fruit juice drinks, or vegetable drinks. These ingredients may be used independently or in combination.

The proportion of these additives is not particularly important, but is typically selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health beverage composition of the present invention.

In the present invention, prevention or improvement of sarcopenia may be achieved by increasing the weight and improving the muscle strength of the thigh muscle.

Therefore, the oat hull extract provided in the present invention can be effectively used for preventing or improving muscle disease.

Another aspect of the present invention provides a pharmaceutical composition for preventing or treating muscle disease, comprising an oat hull extract as an active ingredient.

At this time, the oat hull, extract, muscle disease and prevention are as described above.

The term "treatment" of the present invention means any action whereby the symptoms of a subject suspected of having or suffering from a muscle disease are improved or beneficially changed by administration of the pharmaceutical composition.

The pharmaceutical composition of the present invention may contain the extract in an amount of 0.001 to 80 wt%, specifically 0.001 to 70 wt%, and more specifically 0.001 to 60 wt%, based on the total weight of the composition, but is not limited thereto.

In addition, the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier, excipient or diluent commonly used in the manufacture of pharmaceutical compositions, and the carrier may comprise a non-naturally occurring carrier. The carrier, excipient and diluent may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

In addition, the pharmaceutical composition may be formulated and used in the form of tablets, pills, powders, granules, capsules, suspensions, oral solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, transdermal absorbents, gels, lotions, ointments, creams, patches, cataplasmas, pastes, sprays, skin emulsions, skin suspensions, transdermal delivery patches, drug-containing bandages or suppositories, respectively, according to conventional methods. Specifically, when formulating, the composition may be prepared using diluents or excipients such as fillers, weighting agents, binders, wetting agents, disintegrating agents, and surfactants that are commonly used. Solid preparations for oral administration include, but are not limited to, tablets, pills, powders, granules, capsules, and the like. These solid preparations can be prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose, lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc can also be used. In addition to liquids for oral administration and liquid paraffin, various excipients such as wetting agents, sweeteners, flavoring agents, preservatives, etc. can be prepared. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspending agents can be used, such as propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases can be used, such as withepsol, macrogol, Tween 61, cacao butter, laurin butter, and glycerogelatin.

Another aspect of the present invention provides a method for preventing or treating muscle disease, comprising administering to a subject other than a human a pharmaceutical composition comprising an oat hull extract as an active ingredient.

At this time, the oat hull, extract and muscle disease are as described above.

In the present invention, the term "subject" may mean any animal, including humans, that has or has developed a muscle disease of the present invention. By administering the pharmaceutical composition of the present invention to a subject, the effects of preventing and treating muscle disease can be obtained.

The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.

The term "administration" in the present invention refers to introducing the pharmaceutical composition of the present invention to a subject by any appropriate method, and the administration route may be through various oral or parenteral routes as long as it can reach the target tissue.

The pharmaceutical composition may be appropriately administered to a subject according to a conventional method, administration route, and dosage used in the art, depending on the purpose or need. Examples of the administration route include oral, parenteral, subcutaneous, intraperitoneal, intrapulmonary, and intranasal administration, and parenteral injection includes intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. In addition, an appropriate dosage and administration frequency may be selected according to a method known in the art, and the amount of the pharmaceutical composition of the present invention actually administered and the administration frequency may be appropriately determined by various factors, such as the type of symptom to be treated, administration route, sex, health condition, diet, age and weight of the subject, and severity of the disease.

The above term, "pharmaceutically effective amount" means an amount sufficient to inhibit or alleviate increased vascular permeability at a reasonable benefit/risk ratio applicable to medical use, and the effective dosage level can be determined according to the subject type and severity, age, sex, activity of the drug, sensitivity to the drug, time of administration, route of administration and excretion rate, treatment period, concurrently used drugs, and other factors well known in the medical field. For example, the oat hull extract can be administered at a dosage of 0.01 to 500 mg/kg per day, specifically 10 to 100 mg/kg, and the administration can be administered once a day or in several divided doses.

The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. And may be administered singly or in multiple doses. It is important to administer an amount that can achieve the maximum effect with the minimum amount without side effects by considering all of the above factors, and this can be easily determined by those skilled in the art.

The composition of the present invention can be used alone for preventing or treating sarcopenia, or can be used in combination with methods using surgery, hormone therapy, drug therapy, and biological response modifiers.

Another aspect of the present invention provides a feed composition for preventing or improving muscle disease, comprising an oat hull extract as an effective ingredient.

At this time, the oat hull, extract, muscle disease, prevention and improvement are as described above.

The term "feed" of the present invention means any natural or artificial diet, meal, etc. or a component of said meal for eating, ingesting, and digesting by an animal or suitable therefor.

The type of the above feed is not particularly limited, and feed commonly used in the relevant technical field can be used. Non-limiting examples of the above feed include plant feed such as grains, roots, food processing by-products, algae, fibers, pharmaceutical by-products, fats, starches, meal, or grain by-products; and animal feed such as proteins, inorganic substances, fats, mineral substances, fats, single-cell proteins, zooplankton, or food. These may be used alone or in combination of two or more.

The oat hull extract of the present invention included in the feed composition of the present invention may vary depending on the purpose of use and conditions of use of the feed, and for example, may be included in an amount of 0.01 to 100 wt%, more specifically, 1 to 80 wt%, based on the total weight of the livestock feed composition.

The preventive or therapeutic pharmaceutical composition containing the oat hull extract of the present invention as an active ingredient provides an increase in the weight and improvement in muscle strength of the thigh muscle and has the effect of restoring a reduced muscle cross-sectional area, and therefore can be provided as a composition for preventing, improving, or treating muscle diseases.

Figure 1 is a graph showing the cytotoxicity of oat hull extract at different concentrations.
Figure 2 is a graph showing the effect of oat hull extract on the expression level of Atrogin-1 in a test tube.
Figure 3 is a graph showing the effect of oat hull extract on the expression level of MEF2 in a test tube.
Figure 4 is a graph showing the effect of oat hull extract on the expression level of MuRF1 in a test tube.
Figure 5 is a graph showing the effect on the weight of liver tissue and thigh muscle tissue in vivo .
Figure 6 is a graph showing the results of analyzing inflammatory cytokines in the thigh muscle in vivo .

Hereinafter, the present invention will be described in more detail through examples. These examples are intended to explain the present invention more specifically, and the scope of the present invention is not limited by these examples.

Example 1: Preparation of oat hull extract

Example 1-1: Preparation of oat hull alcohol extract

2 L of nucleic acid was added to 1 kg of oat hulls, extracted by stirring at room temperature for 24 hours, filtered through a filter paper, the filtrate was discarded, and this process was repeated 3 times. After that, ethanol and 50% ethanol, a solvent 10 times that of oat hulls, were added to the filtered oat hulls, extracted by stirring at room temperature for 24 hours, and then filtered through a filter paper. This process was repeated 3 times, and all the filtrates were collected and concentrated using a vacuum concentrator to produce a brown, mucilaginous ethanol extract.

Example 1-2: Preparation of oat hull water extract

Distilled water was added to 1 kg of oat hulls (Jeongeup Oat Premium Product Development Group) in an amount 10 times that of the oat hulls, stirred at room temperature for 24 hours, extracted, filtered through a filter paper, and this process was repeated three times. All the residues were collected and concentrated using a depressurizing evaporator to produce a water extract.

Example 2: Cytotoxicity assay

In order to evaluate the toxicity of oat hull extract to cells, the extract prepared in Example 1 was treated to C2C12 cells and cell viability was measured. Cell viability was measured using a CCK-8 assay, and the results are shown in Fig . 1. The oat hull extracts treated at Nos. 1 to 6 in Fig. 1 are as shown in Table 1 below.

Number name 1 Oat hull 0% alcohol (water extract) 2 10% oat hull spirit 3 20% oat hulls 4 30% oat hulls 5 40% oat hull spirit 6 50% oat hull spirit

As a result, as shown in Fig. 1, it was confirmed that the oat hull water extract and alcohol extract did not exhibit cytotoxicity with a survival rate of at least 80% or higher.

Example 3: Analysis of the efficacy of oat hull extract to improve muscle loss in vitro

In order to confirm the efficacy of oat hull extract to improve muscle loss, the expression levels of MyoD, MEF2, Atrogin-1, and MuRF1, which are biomarkers related to sarcopenia, were confirmed by real-time qPCR using the C2C12 cells of Example 2. At this time, the oat hull extract was treated at a concentration of 10 μg/mL.

As a result, as can be confirmed in FIGS. 2 and 3, it was confirmed that the muscle atrophy-related gene Atrogin-1, which was increased by dexamethasone treatment, was reduced by about 20% by oat hull water extract, and it was confirmed that the decreased MEF2 expression was increased by treatment with oat hull water extract and ethanol extract.

In addition, as can be confirmed in Fig. 4, MuRF1 was increased by dexamethasone treatment, but its expression was significantly reduced by the oat hull extract treatment of the present invention, and it was confirmed that it was reduced more effectively in particular in the oat hull water extract.

Based on these results, it can be confirmed that the oat hull extract of the present invention exhibits a muscle loss inhibition effect, and in particular, the water extract has a superior muscle loss inhibition effect than the alcohol extract.

Example 4: in vivo Analysis of the efficacy of my oat hull extract to improve muscle loss

Example 4-1: Test materials and methods

1) Experimental sample

The oat hull extract used as the experimental sample was dissolved in saline solution (0.9% NaCl) at concentrations of 250 and 500 mg/kg and orally administered once daily for the 2nd and 3rd weeks of inducing muscle loss.

Schisandra chinensis powder was dissolved in saline solution at a concentration of 500 mg/kg and administered orally as a positive control group (Table 2 below).

Group Mice Treatment Induction of muscle loss Normal group (N) 5 - (-) Muscle loss control (C) 5 - Positive control group (P) 5 Omija 500 mg/kg (+) OL (low concentration oat hull) 5 Oat hull 250 mg/kg OH (high concentration of oat hulls) 5 Oat hull 500 mg/kg

2) Laboratory animals

During breeding, the lighting time was set to a 12-hour cycle (07:00 ~ 19:00), and feed and water were provided ad libitum.

3) Inducing muscle loss

To create a muscle wasting animal model, an immobilization device was created using a 1.5 ml microfuge tube, a metal paperclip, and a velcro loop according to the method of You et al. 1) (Disease models & mechanisms, 8(9), 1059-1069. 2015). The created device was applied to the right hind limb to impose restriction of movement for 2 weeks.

4) End of test and collection of biological samples

After the experiment, the test animals were anesthetized with CO2 gas and treated. Blood was collected from the abdominal aorta, placed in a serum separation tube, and left at room temperature for 30 minutes. Then, the serum was separated by centrifugation at 1,700 x g for 15 minutes. In addition, the liver and femoral muscle were removed, weighed, and stored frozen.

5) Analysis of inflammatory cytokines in the thigh muscle

The content of inflammatory cytokines in the thigh muscles of experimental animals induced with muscle loss was determined. The contents of TNF-α (Cat no. MBS825075, Mybiosource, CA, USA) and IL-6 (Cat no. ab46100, abcam, MA, USA) were measured using ELISA kits.

Tissue supernatants were added to 96-well plates coated with each antibody and incubated at room temperature for 2 hours. After incubation, the plates were washed with wash buffer, conjugates were added, and incubated for 2 hours. After 2 hours, the plates were washed with wash buffer, substrate solution was added, and incubated for 30 minutes in a light-blocking condition. After 30 minutes, stop solution was added, and optical density (OD) was measured at 450 nm using a microplate reader.

6) Observation of gene expression in the thigh muscle

To confirm the expression levels of MuRF1, atrogin-1, myostatin, and MAFbx in the thigh muscles of experimental animals induced with muscle loss, qPCR analysis was performed. Muscle tissues were extracted, trizol reagent (Cat No. 15596 -026, Invitrogen, USA) was added, and the supernatant was centrifuged to extract RNA. After measuring the amount of RNA and protein using Nano drop, cDNA was synthesized using Prime -Script™ RT Master Mix (Cat No. RR036A, Takara, USA). After cDNA synthesis, the level of gene expression was measured using a real-time PCR equipment. The primer sequences used at this time are as follows in Table 3 below (each sequence in Table 3 below is SEQ ID NO: 1 to 10, and the first sequence is SEQ ID NO: 1 and increases by one in sequence).

7) Statistical processing

Statistical tests were performed using the Statview (ver.5.0.1) statistical program, and the measured values were expressed as the mean ± standard deviation. Statistical significance for each analysis item was tested post hoc using Fisher’s PLSD method at the p<0.05 level after performing the ANOVA test.

Example 5-2: Confirmation of muscle reduction efficacy

1) Weight change

Table 4 below shows the results of examining the change in body weight by group of mice while administering Schisandra chinensis and oat hull extracts to experimental animals and inducing muscle loss. As can be seen in Table 4, in the group in which muscle loss was induced, the change in body weight during the experimental period was significantly (p<0.05) reduced compared to the N group, and when the oat hull extract of the present invention (OL-low concentration oat hull water extract, OH-high concentration oat hull water extract) was administered, it was confirmed that the body weight increased compared to the C group in which muscle loss was induced.

2) Tissue weight

As can be seen in Figure 5, in contrast to the fact that no significant difference was observed in any group for liver tissue, the weight of the thigh muscle significantly (p<0.05) increased in all groups administered oat hull extract compared to group C.

These results suggest that the administration of oat hull extract significantly increases the weight of the thigh muscle, which is very effective in treating and improving muscle loss.

3) Analysis of inflammatory cytokines in the thigh muscle

As confirmed in Fig. 6, the concentration of TNF-α in the thigh muscle significantly (p<0.05) increased in the C group (66.50 ± 19.28 pg/mL), which induced muscle loss, compared to the N group (34.92 ± 3.33 pg/mL), which did not induce muscle loss. In addition, it was confirmed that all groups treated with the oat hull extract of the present invention showed a significant (p<0.05) decrease compared to the C group, confirming that the oat hull extract effectively reduces inflammatory cytokines in the thigh muscle.

4) Gene expression analysis (MuRF-1, MaFbx, Myostatin, Atrogin-1)

As a result of analyzing the expression of genes in the thigh muscle, as can be confirmed in Table 5 below, the expression levels of MuRF-1 and MaFbx in the thigh muscle increased in all groups that induced muscle loss compared to the N group, and it was confirmed that the groups treated with the oat hull extract of the present invention (OL, OH) decreased compared to the C group.

In addition, in the case of myostatin, it was confirmed that it significantly decreased in all groups treated with oat hull extract compared to group C, and in the case of atrogin-1, which is induced in the early stage of muscle atrophy, it was confirmed that it significantly (p<0.05) decreased in all groups treated with oat hull extract compared to group C.

Sample MuRF-1/GAPDH MaFbx/GAPDH Myostatin/GAPDH Atrogin-1/GAPDH N 1.007±0.100 1.102±0.106 1.20±0.16 0.960±0.043 C 1.241±0.168 1.321±0.167 1.48±0.17 1.245±0.015 P 1.147±0.034 1.225±0.034 1.36±0.17 1.067±0.032 OL 1.121±0.051 1.261±0.074 1.37±0.10 1.129±0.117 OH 1.199±0.051 1.319±0.066 1.42±0.05 1.128±0.105

Through these results, it can be confirmed that the oat hull alcohol extract and water extract of the present invention are effective in improving muscle strength or reducing muscle mass, and that the oat hull water extract is particularly effective.

From the above description, those skilled in the art will understand that the present invention can be implemented in other specific forms without changing the technical idea or essential characteristics thereof. In this regard, it should be understood that the embodiments described above are exemplary in all respects and not restrictive. The scope of the present invention should be interpreted as including all changes or modifications derived from the meaning and scope of the following claims and their equivalent concepts rather than the above detailed description.

Claims (8)

A food composition for preventing or improving muscle disease, comprising oat hull extract as an active ingredient.
In the first paragraph,
A food composition, wherein the muscle disease is selected from the group consisting of sarcopenia, muscular atrophy, myasthenia, muscular dystrophy, myotonia, hypotonia, muscular dystrophy, amyotrophic lateral sclerosis, muscle wasting, and inflammatory myopathy.
In the first paragraph,
A food composition, wherein the above extract is extracted with one selected from the group consisting of water, alcohols having 1 to 4 carbon atoms, and combinations thereof.
In the first paragraph,
A food composition wherein the above oat hull extract improves the weight increase and muscle strength of the thigh muscle.

In the first paragraph,
A food composition, wherein the composition further comprises a food additive that is food-wise acceptable.
A pharmaceutical composition for preventing or treating muscle disease, comprising oat hull extract as an active ingredient.
A method for preventing or treating muscle disease, comprising administering an oat hull extract to a subject other than a human.
A feed composition for preventing or improving muscle disease, comprising oat hull extract as an effective ingredient.